Indeed, numerous studies have reported the association between disrupted ROS homeostasis and disease progression, including cardiovascular diseases [23], neurodegenerative diseases [24], metabolic diseases [25], reproductive system diseases [26], digestive diseases [27], respiratory system diseases [28], cancers [29], inflammation [30] and infectious diseases [31]
Mississippi went further: as of August 2023, the state medical board banned off-label prescribing of GLP-1 agonists solely for weight loss
Studies have found that all GLP-1 treatments can lead to weight loss of about 10.5 to 15.8 pounds
Lack of insurance coverage remains one of the greatest barriers to people accessing GLP-1 drugs
Track appetite first, then the scale
Climate Note: Perfect for tropical climates